close :

:

Forgotten your password?
 
Professional Information
A-Z Drug Facts > Desloratadine

Desloratadine

Pronouncation: (dess-lore-AT-ah-deen)
Class: Peripherally selective piperidine

Trade Names:
Clarinex
- Tablets 5 mg

Trade Names:
Clarinex RediTabs
- Tablets, rapidly disintegrating 5 mg

Aerius (Canada)

Pharmacology

Feedback for Desloratadine

As a treatment for... Avg User Ratings [?]
Hay Fever
7.0
Hives Be the first to rate it
Compare with other drugs.
Share your Experience Ask a Question

Long-acting histamine antagonist with selective H 1 -receptor histamine antagonist activity.

Pharmacokinetics

Absorption

T max approximately 3 h. C max approximately 4 ng/mL. AUC approximately 56.9 ng•h/mL.

Distribution

82% to 87% protein bound.

Metabolism

Metabolized to 3-hydroxydesloratadine (active).

Elimination

The t ½ is 27 h. Approximately 87% excreted in urine and feces.

Onset

1 h.

Duration

24 h.

Special Populations

Renal Function Impairment

AUC and C max are increased. Dosage adjustment is recommended.

Hepatic Function Impairment

AUC and t ½ are increased. Dosage adjustment is recommended.

Elderly

C max and AUC are 20% greater. The t ½ is 33.7 h.

Indications and Usage

Relief of nasal and nonnasal symptoms of seasonal and perennial allergic rhinitis; in chronic idiopathic urticaria for relief of symptoms of pruritus and reduction in number and size of hives.

Contraindications

Hypersensitivity to any components of the product or to loratadine.

Dosage and Administration

Adults and Children 12 yr of age and older

PO 5 mg once daily.

Renal/Hepatic impairment

PO 5 mg every other day.

Storage/Stability

Store tablets and orally disintegrating tablets at controlled room temperature (59° to 86°F). Do not remove orally disintegrating tablet from blister until just prior to administration.

Drug Interactions

None well documented.

Laboratory Test Interactions

May prevent or diminish otherwise positive reactions to skin tests.

Adverse Reactions

Cardiovascular

Tachycardia, palpitations (postmarketing).

CNS

Headache (14%); fatigue (5%); dizziness (4%); somnolence (2%).

EENT

Pharyngitis (4%); dry mouth (3%).

GI

Nausea (5%); dyspepsia (3%).

Genitourinary

Dysmenorrhea (2%).

Miscellaneous

Myalgia (3%); hypersensitivity (including rash, pruritus, urticaria, edema, dyspnea, anaphylaxis [postmarketing]).

Precautions

Monitor

Assess patient for allergy symptoms (eg, rhinitis, nasal congestion, sneezing, itching, watery eyes, hives) before starting therapy and periodically throughout therapy. Monitor patient for dizziness and excessive drowsiness. If noted, hold therapy.


Pregnancy

Category C .

Lactation

Excreted in breast milk.

Children

Safety and efficacy not established in children younger than 12 yr of age.

Elderly

Select dose with caution, reflecting greater frequency of decreased hepatic, renal, or cardiac function and comorbidity.

Renal Function

Dosage adjustment is recommended.

Hepatic Function

Dosage adjustment is recommended.

Overdosage

Symptoms

Increased heart rate and corrected QT interval.

Patient Information

  • Advise patient to take dose daily as prescribed and not to stop taking or change the dose unless advised by health care provider.
  • Ensure patient understands how to store and take the orally disintegrating tablet.
  • Advise patient to take without regard to meals but to take with food if stomach upset occurs.
  • Advise patient that if allergy symptoms are not controlled, not to increase the dose of medication or frequency of use but to inform health care provider. Inform patient that larger or more frequent dosing does not increase effectiveness and may cause drowsiness.
  • Caution patient to avoid alcohol and other CNS depressants (eg, sedatives) while using this medication.
  • Caution patient that drug may cause drowsiness and to use caution while driving or performing other tasks requiring mental alertness until tolerance is determined.
  • Advise patient to take frequent sips of water, suck on ice chips or sugarless hard candy, or chew sugarless gum if dry mouth occurs.
  • If patient is to have allergy skin testing, advise not to take the medication for at least 4 days before the skin testing.
  • Instruct patient to stop taking drug and report persistent dizziness or excessive drowsiness to health care provider.



More Desloratadine resources:

Drugs.com Clarinex

PDR Desloratadine

MedFacts Desloratadine

Micromedex Desloratadine - Includes detailed dosage instructions.

FDA Clarinex

Desloratadine Drug Interactions

Compare Desloratadine with other medications for the treatment of:

Hay Fever, Hives

User Reviews:

0 comment(s) about Desloratadine